Podcasts about poisoning and drug reference

Host: John J. Russell, MD Guest: Joseph E. Bavaria, MD Featuring a wide range of disciplines and a new approach to comprehensive care, what do we need to know about the Aorta Center at Penn Medicine? Dr. John Russell is joined by Dr. Joseph E. Bavaria to dive into this aortic program and discuss a new approach to comprehensive care.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Kathryn Gallagher, MS, RN, BSN Guest: Kate Newcomb-DeSanto, MSN, RN, MSW What does Penn Medicine's newly-opened patient room facility have to offer? Dr. Charles Turck is joined by Penn Medicine Clinical Advisors Kathy Gallagher and Kate Newcomb-DeSanto to discuss the new pavilion and how it's revolutionizing patient care.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sandy Marks Guest: Kim Horvath, JD Guest: Kyle Thomson, JD With telehealth services expanding during the COVID-19 pandemic, has our access to them changed? To better understand this, Dr. Charles Turck meets with Sandy Marks, Kim Horvath, and Kyle Thomson from the AMA to explore what's been done to provide Medicare coverage during a public health emergency and what's on the horizon for telehealth access.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Emily Carroll, JD, MSW The No Surprises Act aims to protect consumers from surprise medical bills. But how exactly does it go about doing that, and what's the current status of its implementation? Joining Dr. Charles Turck to share progress and challenges associated with the No Surprises Act is Ms. Emily Carroll, a senior legislative attorney for the American Medical Association's Advocacy Resource Center.

Guest: William Banner, MD, PhD Tissue damage caused by North American pit viper envenomation occurs quickly in snake bite victims. Join Dr. Bill Banner as he discusses three critical aspects of snake bite management and how treatment with CroFab® can be a viable option for patients.

Guest: Spencer Greene, MD, MS, FACEP, FACMT, FAAEM The Unified Treatment Algorithm is a consensus guideline prepared by a panel of experts that provides a simple, step-by-step guide on assessing and treating a patient who’s been bitten by a pit viper. Knowing the correct treatment approach is just as important as understanding what not to do, as Dr. Spencer Greene explains.

Guest: Mark Ryan, PharmD The more time that passes before a snake bite is treated, the higher the risk of long-term or even permanent morbidity due to tissue damage. So when time is tissue, why risk it? Join Dr. Mark Ryan from the Louisiana Poison Control Center as he shares important information on the antivenom CroFab®, including its development, how it quickly controls envenomation effects, and its demonstrated safety profile.

Guest: Spencer Greene, MD, MS, FACEP, FACMT, FAAEM The Unified Treatment Algorithm is a consensus guideline prepared by a panel of experts that provides a simple, step-by-step guide on assessing and treating a patient who’s been bitten by a pit viper. Knowing the correct treatment approach is just as important as understanding what not to do, as Dr. Spencer Greene explains.

Guest: Mark Ryan, PharmD The more time that passes before a snake bite is treated, the higher the risk of long-term or even permanent morbidity due to tissue damage. So when time is tissue, why risk it? Join Dr. Mark Ryan from the Louisiana Poison Control Center as he shares important information on the antivenom CroFab®, including its development, how it quickly controls envenomation effects, and its demonstrated safety profile.

Guest: William Banner, MD, PhD Tissue damage caused by North American pit viper envenomation occurs quickly in snake bite victims. Join Dr. Bill Banner as he discusses three critical aspects of snake bite management and how treatment with CroFab® can be a viable option for patients.

Host: Matt Birnholz, MD Among the most touted candidates in the hunt for effective coronavirus treatments are the antimalarial drugs chloroquine and its derivative, hydroxychloroquine. Will these drugs become effective treatment and post-exposure prophylaxis agents? Published March 23, 2020

Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens" As physicians, we know that vaccines help protect people from preventable diseases, but somehow this message is getting lost among our patients. With more parents than ever choosing to skip the needle, Dr. Andrew Wilner dives into the 16th chapter of his book, Bullets and Brains, where he discusses the widespread benefits of vaccines and how they not only protect your patients’ children, but all of us.

Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens" As physicians, we know that vaccines help protect people from preventable diseases, but somehow this message is getting lost among our patients. With more parents than ever choosing to skip the needle, Dr. Andrew Wilner dives into the 16th chapter of his book, Bullets and Brains, where he discusses the widespread benefits of vaccines and how they not only protect your patients’ children, but all of us.

Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens" Up until 2011, there was no FDA-approved antivenom for scorpion stings—until a very concerned pediatrician created one that came with seemingly miraculous results. Dr. Andrew Wilner breaks down this overlooked health threat and the development of its antivenom, which he explores in his book of essays called Bullets and Brains.

Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens" Up until 2011, there was no FDA-approved antivenom for scorpion stings—until a very concerned pediatrician created one that came with seemingly miraculous results. Dr. Andrew Wilner breaks down this overlooked health threat and the development of its antivenom, which he explores in his book of essays called Bullets and Brains.

The FDA has made strides in improving transparency and data access, and has implemented tools to allow the pharmaceutical industry and the public to transform raw data into usable information. One of these tools is called the FDA Adverse Event Reporting System (FAERS) Public Dashboard. In this episode, the architects of the FAERS Public Dashboard – Deputy Director of the Regulatory Science Staff Suranjan De, and Acting Team Lead in Regulatory Science Information Sanjay Sahoo—both of CDER’s Office of Surveillance and Epidemiology, highlight their work with this new online tool.

The Food and Drug Administration (FDA) is warning that the medicine lamotrigine (Lamictal) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body's infection-fighting immune system. This can cause severe inflammation throughout the body and lead to hospitalization and death, especially if the reaction is not diagnosed and treated quickly. A link to the full communication detailing specific information for health care professionals and a list of FDA-approved GBCAs can be found at www.fda.gov/Drugs/DrugSafety Released 4/25/2018

The Food and Drug Administration (FDA) is warning that the medicine lamotrigine (Lamictal) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s infection-fighting immune system. This can cause severe inflammation throughout the body and lead to hospitalization and death, especially if the reaction is not diagnosed and treated quickly. A link to the full communication detailing specific information for health care professionals and a list of FDA-approved GBCAs can be found at www.fda.gov/Drugs/DrugSafety Released 4/25/2018

The Food and Drug Administration (FDA) is warning that the medicine lamotrigine (Lamictal) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s infection-fighting immune system. This can cause severe inflammation throughout the body and lead to hospitalization and death, especially if the reaction is not diagnosed and treated quickly. A link to the full communication detailing specific information for health care professionals and a list of FDA-approved GBCAs can be found at www.fda.gov/Drugs/DrugSafety Released 4/25/2018

Host: Maurice Pickard, MD Guest: Carl Hart, MD Carl Hart, who grew up in one of Miami’s toughest neighborhoods, escaped a life of crime and drugs and avoided becoming one of the crack addicts he now helps treat as the Chair of the Department of Psychology at Columbia University. His landmark, controversial research is redefining our understanding of addiction and demonstrates how personal experience and scientific study can inform and validate each other for a deeper understanding of human behavior and addiction. Host Dr. Maurice Pickard talks with Dr. Hart, author of the book High Price, about the relationship between drugs and pleasure, choice, and motivation, both in the brain and in society. They explore how his research sheds new light on common ideas about race, poverty, and drugs, and explain why current policies are failing.

Host: Maurice Pickard, MD Guest: Carl Hart, MD Carl Hart, who grew up in one of Miami's toughest neighborhoods, escaped a life of crime and drugs and avoided becoming one of the crack addicts he now helps treat as the Chair of the Department of Psychology at Columbia University. His landmark, controversial research is redefining our understanding of addiction and demonstrates how personal experience and scientific study can inform and validate each other for a deeper understanding of human behavior and addiction. Host Dr. Maurice Pickard talks with Dr. Hart, author of the book High Price, about the relationship between drugs and pleasure, choice, and motivation, both in the brain and in society. They explore how his research sheds new light on common ideas about race, poverty, and drugs, and explain why current policies are failing.

Host: Maurice Pickard, MD Guest: Carl Hart, MD Carl Hart, who grew up in one of Miami’s toughest neighborhoods, escaped a life of crime and drugs and avoided becoming one of the crack addicts he now helps treat as the Chair of the Department of Psychology at Columbia University. His landmark, controversial research is redefining our understanding of addiction and demonstrates how personal experience and scientific study can inform and validate each other for a deeper understanding of human behavior and addiction. Host Dr. Maurice Pickard talks with Dr. Hart, author of the book High Price, about the relationship between drugs and pleasure, choice, and motivation, both in the brain and in society. They explore how his research sheds new light on common ideas about race, poverty, and drugs, and explain why current policies are failing.

Host: Maurice Pickard, MD Guest: Carl Hart, MD Carl Hart, who grew up in one of Miami’s toughest neighborhoods, escaped a life of crime and drugs and avoided becoming one of the crack addicts he now helps treat as the Chair of the Department of Psychology at Columbia University. His landmark, controversial research is redefining our understanding of addiction and demonstrates how personal experience and scientific study can inform and validate each other for a deeper understanding of human behavior and addiction. Host Dr. Maurice Pickard talks with Dr. Hart, author of the book High Price, about the relationship between drugs and pleasure, choice, and motivation, both in the brain and in society. They explore how his research sheds new light on common ideas about race, poverty, and drugs, and explain why current policies are failing.

Host: Brian P. McDonough, MD, FAAFP According to a report from the Trust for America’s Health, an estimated 1.6 million people could die from drugs, alcohol, and suicide in the next ten years. This is a 60% increase from the past decade. Host Dr. Brian McDonough talks with John Templeton Jr, President of Footprints Beachside Recovery Center in Florida, about treating addiction and what doctors need to know about reducing opioid addiction risk in their pain medication management.

Host: Brian P. McDonough, MD, FAAFP Over 33,000 lives were lost to opioid overdose in 2015, translating into 91 people dying each day, according to the most recent CDC data. Reducing exposure to prescription opioids, for situations where the risks of opioids outweigh their benefits, is a crucial part of reversing this trend. Host Dr. Brian McDonough explores alternative options to prescription opioids with addiction specialist Dr. Isaac Alexis, Medical Director of the Lifeline Addiction Center in Beckley, WV.

Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer. Released on December 21, 2017

Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer. Released on December 21, 2017

Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer. Released on December 21, 2017

Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer. Released on December 21, 2017

Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer. Released on December 21, 2017

Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer. Released on December 21, 2017

Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer. Released on December 21, 2017

The FDA announced that it is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (or MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs. Report side effects involving GBCAs to FDA’s MedWatch program at www.fda.gov/medwatch. A link to the full communication detailing specific information for health care professionals and a list of FDA approved GBCAs can be found at www.fda.gov/DrugSafety. Released 12/19/2017

The FDA announced that a review of four large clinical safety trials shows that treating asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly more serious asthma-related side effects than treatment with ICS alone. A link to the full communication detailing information for health care professionals and the Data Summary can be found at www.fda.gov/DrugSafetyCommunications. Released 12/20/2017

Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. Vavricka SR1, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, Greuter T; Swiss IBD Cohort Study Group. BACKGROUND: Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequently observed. Little is known about the efficacy of anti-tumor necrosis factor (TNF) in EIM management. We assessed the effect of 3 anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) on EIM evolution. METHODS: Data on 1249 patients from the Swiss IBD Cohort Study (SIBDCS) were analyzed. All EIMs were diagnosed by relevant specialists. Response was classified into improvement, stable disease, and clinical worsening based on the physician's interpretation. RESULTS: Of the 366 patients with at least 1 EIM, 213 (58.2%) were ever treated with an anti-TNF. A total of 299 treatments were started for 355 EIMs. Patients with EIM were significantly more often treated with anti-TNF compared with those without EIM (58.2% versus 21.0%, P < 0.001). ...

Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. Vavricka SR1, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, Greuter T; Swiss IBD Cohort Study Group. BACKGROUND: Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequently observed. Little is known about the efficacy of anti-tumor necrosis factor (TNF) in EIM management. We assessed the effect of 3 anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) on EIM evolution. METHODS: Data on 1249 patients from the Swiss IBD Cohort Study (SIBDCS) were analyzed. All EIMs were diagnosed by relevant specialists. Response was classified into improvement, stable disease, and clinical worsening based on the physician's interpretation. RESULTS: Of the 366 patients with at least 1 EIM, 213 (58.2%) were ever treated with an anti-TNF. A total of 299 treatments were started for 355 EIMs. Patients with EIM were significantly more often treated with anti-TNF compared with those without EIM (58.2% versus 21.0%, P < 0.001). ...

Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. Vavricka SR1, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, Greuter T; Swiss IBD Cohort Study Group. BACKGROUND: Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequently observed. Little is known about the efficacy of anti-tumor necrosis factor (TNF) in EIM management. We assessed the effect of 3 anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) on EIM evolution. METHODS: Data on 1249 patients from the Swiss IBD Cohort Study (SIBDCS) were analyzed. All EIMs were diagnosed by relevant specialists. Response was classified into improvement, stable disease, and clinical worsening based on the physician's interpretation. RESULTS: Of the 366 patients with at least 1 EIM, 213 (58.2%) were ever treated with an anti-TNF. A total of 299 treatments were started for 355 EIMs. Patients with EIM were significantly more often treated with anti-TNF compared with those without EIM (58.2% versus 21.0%, P < 0.001). ...

Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. Vavricka SR1, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, Greuter T; Swiss IBD Cohort Study Group. BACKGROUND: Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequently observed. Little is known about the efficacy of anti-tumor necrosis factor (TNF) in EIM management. We assessed the effect of 3 anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) on EIM evolution. METHODS: Data on 1249 patients from the Swiss IBD Cohort Study (SIBDCS) were analyzed. All EIMs were diagnosed by relevant specialists. Response was classified into improvement, stable disease, and clinical worsening based on the physician's interpretation. RESULTS: Of the 366 patients with at least 1 EIM, 213 (58.2%) were ever treated with an anti-TNF. A total of 299 treatments were started for 355 EIMs. Patients with EIM were significantly more often treated with anti-TNF compared with those without EIM (58.2% versus 21.0%, P < 0.001). ...

Many listeners may be familiar with the FDA's Adverse Event Reporting System or FAERS. Data in FAERS supports the FDA's post-marketing safety surveillance program for drug products and therapeutic biologic products. Recently, CDER's Office of Surveillance and Epidemiology created and released a tool that makes FAERS data easier to query and retrieve. This new interactive dashboard is designed to expand access of FAERS data to the general public. Dr. Janet Woodcock, Director of the FDA Center for Drug Evaluation and Research, discusses the advantages of the tool as well as its limitations.

Host: Brian P. McDonough, MD, FAAFP Every year, 1 in 6 Americans get sick from eating contaminated food. USDA Food Safety expert Sarah Lichtman joins host Dr. Brian McDonough to discuss ways to safely handle food, prevent food poisoning, and minimize risk of foodborne illnesses.

Host: Brian P. McDonough, MD, FAAFP Every year, 1 in 6 Americans get sick from eating contaminated food. USDA Food Safety expert Sarah Lichtman joins host Dr. Brian McDonough to discuss ways to safely handle food, prevent food poisoning, and minimize risk of foodborne illnesses.

Host: Brian P. McDonough, MD, FAAFP Every year, 1 in 6 Americans get sick from eating contaminated food. USDA Food Safety expert Sarah Lichtman joins host Dr. Brian McDonough to discuss ways to safely handle food, prevent food poisoning, and minimize risk of foodborne illnesses.

FDA medical oncologists discuss the July 7, 2017, approval of l-glutamine to reduce the acute complications of sickle cell disease. Released August 17, 2017

Based on new data from two large clinical trials, the FDA concluded that the type 2 diabetes medicine canagliflozin (brand names Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. The FDA is requiring new warnings, including their most prominent Boxed Warning, be added to the canagliflozin drug labels to describe this risk. Amputations of the toe and middle of the foot were the most common; however, amputations involving the leg, below and above the knee, also occurred. Some patients had more than one amputation, some involving both limbs. Report side effects involving canagliflozin and other medicines to the FDA MedWatch program at fda.gov/medwatch. A link to the full communication detailing specific information for health care professionals and the complete Data Summary can be found at fda.gov/DrugSafetyCommunications. If you have drug questions, contact the FDA at druginfo@fda.hhs.gov. Released 5/16/2017

In this session of Beyond the Data carrying forward ideas discussed at CDC's Public Health Grand Rounds, Dr. Phoebe Thorpe and Dr. Larry Garber expand on the reasons for medication non-adherence by patients, and priority considerations for helping reduce this risk.

Host: Alan S. Brown, MD, FACC, FAHA, FNLA Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Eugenia Gianos. Dr. Gianos is an assistant professor in the Department of Medicine and co-clinical director of the Center for the Prevention of Cardiovascular Disease at the NYU School of Medicine. Dr. Gianos discusses the effectiveness, potential side effects, and patient outcomes with PCSK9 antibodies for management of dyslipidemia.

Host: Michael Krychman, MD There are many herbs and supplements that have gained popularity as natural sexual aphrodisiacs. While many are sold over the counter nationwide to enhance sexual function, a surprising number of supplements can cause ranges of serious side effects. Which aphrodisiacs have been proven effective, which are safe, and which are potentially deadly? Host Dr. Michael Krychman joins Dr. Elizabeth West, a resident physician at the University of California-Irvine, to talk about the spectrum of natural herbs and supplements, from foods like honey and chocolate to herbs such as ginseng and macca, and their known sexual health benefits vs risks.

Guest: Arthur Holden, MBA Host: Bruce Japsen Two years after it was formed, the International Serious Adverse Event Consortium, working with the U.S. Food and Drug Administration, is making progress understanding why certain people are predisposed to dangerous drug interactions. Arthur Holdren, founder of the consortium, tells host Bruce Japsen about the discovery of a genetic link between liver injury and some people who received a popular antibiotic.

Host: Todd Mahr, MD Guest: Stephen Tilles, MD Aspirin is something widely used in everyday practice, and generally well-tolerated. Yet, potentially serious adverse effects - sometimes leading to hospitalization - exist. Who's at risk? What are the symptoms, and can Aspirin desensitization work for all patients? Join Dr. Todd A. Mahr as he speaks with Dr. Stephen Tilles, clinical assistant professor at the University of Washington School of Medicine, in a discussion of aspirin intolerance.

Host: Todd Mahr, MD Guest: Stephen Tilles, MD How common is Aspirin Intolerance? When was it first discovered, and what are the clinical manifestations? Dr. Stephen Tilles, clinical assistant professor at the University of Washington School of Medicine, joins Dr. Todd A. Mahr to discuss aspirin intolerance, highlighting symptoms and provocative testing.